![Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-018-0061-6/MediaObjects/41416_2018_61_Fig1_HTML.jpg)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
![A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ] A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2019/7837/1/fig-2-full.png)
A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]
![Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/356259194/figure/fig2/AS:1091002400022593@1637126650745/Overall-survival-plot-Kaplan-Meier-curve-is-shown-for-overall-survival-in-patients-with.png)
Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram
![Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology](https://www.journal-of-hepatology.eu/cms/asset/734a0236-aae1-490d-bbfe-b8cf04ab02e7/ga1.jpg)
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology
![Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/d50ddc69-3da5-4069-b52c-375cde0fc19c/gr2_lrg.jpg)
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
![Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial - Kiyota - 2022 - Cancer - Wiley Online Library Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial - Kiyota - 2022 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ea8bc1f-ec67-4b1d-a1b6-7f66a1419417/cncr34181-fig-0001-m.jpg)
Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial - Kiyota - 2022 - Cancer - Wiley Online Library
![Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-018-0360-y/MediaObjects/41416_2018_360_Fig1_HTML.png)
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer
![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F1.large.jpg)
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![Cancers | Free Full-Text | Role of Postoperative Complications in Overall Survival after Radical Resection for Gastric Cancer: A Retrospective Single-Center Analysis of 1107 Patients Cancers | Free Full-Text | Role of Postoperative Complications in Overall Survival after Radical Resection for Gastric Cancer: A Retrospective Single-Center Analysis of 1107 Patients](https://pub.mdpi-res.com/cancers/cancers-11-01890/article_deploy/html/images/cancers-11-01890-g001.png?1577711161)
Cancers | Free Full-Text | Role of Postoperative Complications in Overall Survival after Radical Resection for Gastric Cancer: A Retrospective Single-Center Analysis of 1107 Patients
![Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK562120/bin/493434_1_En_1_Fig3_HTML.jpg)
Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf
![Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of](https://ars.els-cdn.com/content/image/1-s2.0-S0959804914008727-gr1.jpg)
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
![Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) - Annals of Oncology Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/647541f0-0bf4-4895-b1c9-092ab47e78d7/gr1.jpg)